EASME

Agade specializes in the development of robotic exoskeletons aimed at reducing muscle fatigue and minimizing the risk of injuries linked to repetitive and dynamic tasks. Their flagship product, AGADEXO, is designed to provide variable support for upper limb movements, effectively counteracting the effects of gravity and allowing for more efficient motion, akin to operating in a zero-gravity environment. The exoskeleton is compact and energy-efficient, consuming minimal power comparable to that of medium-intensity LED bulbs. This innovative technology is particularly beneficial for operators engaged in pick and place tasks, enhancing productivity while safeguarding against the physical strain associated with their work.

Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Healthplus.ai specializes in a surgical patient risk management platform that leverages electronic health record data to enhance surgical care. By utilizing AI and machine learning algorithms, the platform integrates seamlessly with existing EHR workflows to predict potential complications following surgery. This proactive approach allows healthcare professionals to identify early warnings of post-surgery infections and other significant risks, thereby improving patient outcomes and reducing overall costs. Healthplus.ai's technology empowers clinical staff to deliver tailored support to patients, ultimately fostering a more effective and efficient surgical care environment.

TomoWave is a company focused on developing innovative imaging technologies for clinical medicine and preclinical research. Utilizing its proprietary optoacoustic and laser ultrasonic imaging modalities, TomoWave aims to enhance cancer detection, guide medical interventions, and monitor the effectiveness of cancer therapies. The company's technology, which captures images by "listening to the sound of light," allows for highly detailed visualization of tissues, particularly in relation to vascular and blood-related conditions. Founded by Dr. Alexander Oraevsky, a pioneer in biomedical optoacoustics, TomoWave has a strong emphasis on generating intellectual property and advancing it from concept to validated clinical prototypes. The company is committed to bringing its technologies to market through appropriate regulatory certifications, thus contributing to improved diagnostic capabilities in healthcare.

Somax Systems specializes in the development and commercialization of high-performance ultrasound imaging devices tailored for the healthcare sector. The company is on the verge of launching a pocket-sized scanner that is expected to become an essential tool for health professionals, akin to the stethoscope or thermometer. This innovative device offers high-resolution imaging with real-time zoom capabilities and allows for wireless data transmission via Wi-Fi, enhancing the efficiency of healthcare providers. Somax Systems is committed to delivering superior quality products that meet the needs of users and provide sustainable value, grounded in principles of trust, innovation, creativity, and entrepreneurship.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

ZygoFix is a medical device company focused on spine technology. It has developed a three-dimensional printed implant designed to lock the facet joint of the lumbar spine. This innovative device leverages the anatomy of the spine to provide stability, moving away from traditional external screw-based systems. By eliminating the need for pedicle screws, ZygoFix aims to reduce the risks associated with improper screw placement, enhancing patient safety and outcomes in spinal surgeries.

Surgitate specializes in the manufacture of synthetic models aimed at enhancing the training experience for medical and veterinary students, as well as healthcare professionals such as nurses and obstetricians. The company produces a range of models, including synthetic skin, breast, and vascular components, designed to simulate realistic surgical procedures, including incision, dissection, and suturing. This hands-on practice enables users to develop their skills in a controlled environment. Founded by a materials engineer and a thoracic surgeon, Surgitate benefits from the expertise of its investors, Farplas, a leader in plastic automotive parts manufacturing, and Inovent, a pioneer in technology commercialization and seed funding in Turkey. Farplas provides essential support in process development and mass production, while Inovent facilitates connections with potential investors and assists in business and marketing strategies.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

ConquerX is a biotechnology company that specializes in innovative molecular profiling solutions aimed at enhancing clinical trials in precision medicine. The company offers a flagship product, the EbeGen, which is an electro-chemical biosensor capable of simultaneously detecting various molecular targets, including DNAs, RNAs, and mirRNAs, without the need for sequencing or qPCR. This technology is ten times more cost-effective compared to traditional methods. Additionally, ConquerX has developed a pan-cancer test designed to differentiate between cancerous and healthy cells. Using high-throughput genomic and proteomic profiling along with proprietary nanotechnology, this tool enables oncologists to screen established biomarkers across various cancer types, thereby improving the accuracy and efficiency of cancer diagnoses.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of innovative hearing solutions tailored for individuals with varying degrees of hearing impairment. Originating as a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic Tübingen, Vibrosonic focuses on creating discreet hearing devices that integrate advanced microsystem technologies. Their unique approach involves the use of piezoelectric principles to design hearing contact lenses that can be directly placed on the eardrum. This technology transmits sound through vibrations rather than traditional speakers, enhancing the auditory experience while minimizing discomfort for users. Through its specialized equipment, Vibrosonic aims to improve the quality of life for those affected by hearing loss.

BalanSeat is a medical device developed by MoPair Technologies Ltd., a company founded by a Feldenkrais practitioner with extensive experience in treating neurologically impaired patients, including those with Multiple Sclerosis, Post-Stroke effects, and Parkinson’s disease. The device is designed specifically for the elderly and individuals with neurological impairments, aiming to enhance walking quality, improve balance, and reduce the risk of falls. BalanSeat achieves this by applying rotational movement between the pelvis, trunk, and thighs, which emulates normal walking patterns while the user remains seated. This innovative approach helps older adults regain essential balance and upper-body rotational movement, contributing to their overall mobility and safety.

Waterscope is a not-for-profit impact-defined company based in Cambridge. Waterscope is a Cambridge University spin-out developing easy-to-use, rapid water testing microscopes capable of identifying bacterial presence in drinking water. Their bacterial imaging device can identify specific bacterial micro-colonies in less than 6 hours, four times faster than current gold-standard portable systems. Their system is automated, not requiring significant user training. Using image recognition software, bacterial colonies can be automatically identified and counted. Once data is collected the bacterial imaging device will automatically upload and disseminate results for mapping or intervention. THeir novel bacterial cartridge simplifies bacterial testing eliminating the need for a central lab and significant user training.

Hystrix Medical operates a digital marketplace that connects healthcare organizations with suppliers of medical devices and consumable products. This platform streamlines the procurement process, significantly reducing the time required for purchasing from the typical 4-6 months to a more efficient system. By providing a transparent market price landscape and facilitating one-stop contracting, Hystrix Medical enhances the efficiency of hospital procurement personnel and suppliers. The platform focuses on products that require minimal explanation, allowing for straightforward transactions. Users have reported average total cost savings of 40%, highlighting the platform's effectiveness in optimizing purchasing processes and fostering better trade relationships in the healthcare sector.

MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

Kheiron Medical Technologies Limited is a company focused on enhancing breast cancer detection through its innovative product, Mia, an intelligent assessment tool for mammography. Incorporated in 2016 and based in London with additional offices in San Francisco, Budapest, and Amsterdam, Kheiron aims to improve the efficiency, consistency, and accuracy of radiology reporting by integrating advanced deep learning techniques with radiological expertise. The company's mission is to radically enhance outcomes for cancer patients by advancing precision radiology, thereby providing women with better chances in the fight against cancer. Through ongoing research and development, Kheiron strives to transform cancer detection and treatment, marking a significant step forward in the realm of healthcare technology.

Next Generation Sensors is a biotech business that creates mass spectrometers for commercial uses in the life sciences. Finding rapid, accurate screening information for potential health, security, and environmental hazards relies on. By bringing the lab to the sample with portable, sensitive, accurate, and user-friendly technology for quick detection of dangerous compounds in our food, bodies, and environment, offers answers for a safer future.

MyoSwiss AG, founded in 2017 and based in Zurich, Switzerland, specializes in medical technology aimed at enhancing mobility for individuals with muscle weakness. The company develops innovative products such as the Myofit and Myosuit, which serve as advanced training devices for rehabilitation and physiotherapy. These devices are designed to improve the quality of life for users by providing an additional layer of muscle support, thereby enabling them to regain their mobility and independence. MyoSwiss also offers personalized training plans, intensive activity-based training, and performance tracking to enhance the effectiveness of its solutions, helping individuals with mobility impairments realize their potential for physical activity.

Lucine is focused on transforming patient health, primarily in the area of pain management. The company has developed a mobile health application that measures, analyzes, and alleviates pain from the comfort of home. Utilizing advanced algorithms, the application identifies the nature of a patient's pain by analyzing facial expressions, vocal cues, and posture. Based on this real-time assessment, it personalizes treatment options, offering techniques such as exercises, relaxation methods, art therapy, and meditation. The application aims to provide relief within five minutes through innovative analgesic neurostimulation, empowering patients with chronic pain to manage their symptoms effectively.

Advanced Microfluidics, based in Ecublens, Switzerland, is a machinery manufacturing company that specializes in developing and producing high-end lab equipment components. Their primary focus is on automated liquid handling systems, which are designed to minimize cross-contamination and reduce internal volume, ensuring precise and efficient fluidic performance. The company's products cater to both laboratory and industrial sectors, providing solutions with no dead volumes.

Polymer Factory, established in 2006 at the Royal Institute of Technology in Stockholm, Sweden, is a prominent supplier of advanced dendritic and polymeric materials, also offering contract research services. Its product range includes monodisperse dendritic polymers derived from 2,2-bis(methylol)propionic acid, such as biocompatible bis-MPA dendrimers and dendrons. The company specializes in the synthesis of high-quality macromolecules, custom materials, and calibrants for MALDI-ToF. Polymer Factory holds exclusive rights to produce, market, and sell several advanced materials, and it globally supplies polyester (Boltorn™) and polyester amide (Hybrane®) hyperbranched polymers for research purposes.

Respinova specializes in the development of non-invasive devices for the treatment of respiratory disorders, particularly chronic obstructive pulmonary disease (COPD). The company's primary product, the PulseHaler, leverages innovative technology that generates dynamic air pressure pulses. These pulses travel quickly through the airways, creating momentary dilating forces that help open collapsed airways and facilitate mucus clearance. By smoothing and spreading the mucus lining within the airways, the PulseHaler aids in airway clearance and reduces the likelihood of airway re-collapse, providing a significant improvement in treatment options for COPD patients.

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

Diabeloop is a medical device company based in Grenoble, France, focused on innovating diabetes treatment through advanced technology. Founded in 2015, the company specializes in developing an AI-based closed-loop system that automates insulin delivery for individuals with type 1 diabetes. This system includes a blood sugar monitoring device that combines a glucose sensor, an insulin pump, and a smartphone application featuring an embedded algorithm. By continuously measuring glucose levels and delivering the appropriate insulin dosage, Diabeloop aims to reduce the mental burden on patients, allowing them to manage their condition more effectively and live their lives with greater ease.

Medfield Diagnostics AB, founded in 2005 by Mikael Persson and Andreas Fhager, specializes in the development and commercialization of diagnostic instruments utilizing microwave technology. The company focuses on advancing stroke diagnostics through its innovative products, including Strokefinder and Impending Applications. By leveraging promising research conducted at Chalmers University of Technology, Medfield Diagnostics aims to enhance the accuracy and efficiency of stroke detection and management.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

ABLE Human Motion is a Barcelona-based medical device start-up founded in 2018 that specializes in the development of robotic exoskeletons designed to improve mobility for individuals with disabilities. The company's primary product, the ABLE Exoskeleton, is a lightweight and user-friendly wearable device that assists paraplegic users in standing, walking, and sitting. This innovative technology employs a motor and gearbox to mimic muscle movement, along with an inertial sensor to interpret the user's intentions. ABLE Human Motion aims to enhance the quality of life for wheelchair users by promoting greater independence and mobility while also providing rehabilitation tools for clinicians to improve treatment efficiency.

Vulcur Medtech is a medical device development company based in Vanløse, Denmark, established in 2018. The company specializes in wound healing through its innovative VMT laser technology, which targets chronic wounds that are otherwise difficult to treat. This advanced device utilizes laser pulses that effectively eliminate biofilm-producing bacteria while preserving healthy human cells, promoting the body's natural healing process. By significantly reducing healing time, Vulcur Medtech enhances the quality of life for patients suffering from chronic wounds.

Stokhos B.V., based in Amsterdam, Netherlands, develops software aimed at optimizing the deployment of emergency vehicles, particularly ambulances. Initially conceived as a scientific mathematical project named REPRO, the company's flagship product, known as seconds, utilizes advanced algorithms to provide real-time coverage advice to emergency dispatch centers. By analyzing factors such as population density, historical incident data, and road networks, Stokhos's platform enables dispatchers to determine the optimal placement of ambulances, ensuring that they can respond swiftly to emergencies within required timeframes. The team at Stokhos is deeply committed to enhancing public safety and has a strong connection to the medical emergency sector, with all members holding valid first aid certifications.

3DBattery is a company that designs, develops, and manufactures portable energy storage solutions, primarily focusing on lithium-ion batteries. Established in 2016 and based in Tel Aviv, Israel, the company specializes in a range of products including rechargeable micro batteries, flexible batteries, and batteries integrated within chips. Their innovative energy storage solutions cater to the needs of various applications, such as flexible and wearable electronics, energy harvesting devices, Internet of Things (IoT) devices, surface-mount technology, and medical equipment. By employing advanced smart material engineering, 3DBattery aims to enhance energy and power efficiency in its products, making them suitable for electric vehicles, grid storage, and other portable electronic devices.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of EmbryoSpin, an innovative device designed for biochemical research. This device performs microscopic nuclear magnetic resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold, allowing for chemical analysis at the scale of a single human embryo. EmbryoSpin is engineered for robustness and user-friendliness, making it suitable for non-invasive embryo viability screening in in-vitro fertilization and various biochemical studies. The company's advancements aim to enhance medical research capabilities, particularly in the context of reproductive health.

BrainPatch is a neurotechnology startup focused on non-invasive brain stimulation. The company develops a computer-brain interface that assists healthcare professionals in measuring brain activity. Its platform integrates artificial intelligence, hardware, and applications, allowing developers, professionals, and patients to conduct brain simulations. This technology aims to facilitate early detection of conditions requiring non-invasive brain stimulation, ultimately aiding patients in their recovery from neurological diseases. BrainPatch recognizes that effective brain stimulation is complex and must be tailored to the individual needs of each patient.

Cardioset Medical is a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema. With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

Spectroplast AG is a Swiss company specializing in the additive printing of pure silicones, offering innovative solutions for a variety of sectors, including healthcare, wearables, industrial components, soft robotics, art, and entertainment. Founded in 2018 and based in Zurich, Spectroplast has developed a unique technology, known as SAMT, that allows for the 3D printing of industry-standard silicones with high precision and performance, without the need for molds. This process not only saves costs and time but also results in zero waste. The company provides a range of silicones with Shore hardness from A0 to A80, available in various colors and transparent options, catering to the specific needs of clients in medical and industrial applications. Through its focus on bridging cutting-edge research and market demands, Spectroplast aims to deliver customized soft material products that meet high performance and quality standards.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

liberDi is an Israeli company that specializes in portable automatic peritoneal dialysis systems designed for patients with end-stage renal disease. The company offers an innovative all-in-one Digital Dialysis Clinic that enables patients to manage their own dialysis with the help of an Intelligent Dialysis Assistant and remote medical supervision. This system allows patients to perform peritoneal dialysis from various locations, including their homes, offices, or while traveling, thereby enhancing their quality of life and reducing reliance on traditional in-clinic care. Founded in 2014 by a team of experts in science and medicine, liberDi aims to free dialysis patients from the constraints of frequent visits to expensive clinics. Its technology not only empowers patients but also helps clinics optimize their operations and reduce costs, creating a comprehensive platform for renal care that benefits both patients and healthcare providers.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

mDurance is a digital health company focused on improving muscle health through innovative technology. It offers a wearable electromyography (EMG) sensor paired with a mobile and web application that facilitates real-time data analysis and cloud storage. The platform enables professionals in physical health, sports, and wellness to verify muscle health, evaluate sports performance through biofeedback, and detect muscle asymmetries. By integrating neuromuscular signal processing with data analytics, mDurance provides objective insights into muscle activity and imbalances, enhancing clinical decision-making. The tool allows for online access from any device, enabling in-depth analysis of a patient's motor control and neuromuscular condition, thereby supporting functional tests in various settings.

SynSense is a neuromorphic computing company based in Zurich, Switzerland, founded in 2017. The company specializes in developing ultra-low-power vision and biosignal processors, as well as point cloud and always-on auditory processing solutions. These products are designed for artificial intelligence edge computing applications, including autonomous robots, mobile and embedded devices, wearable healthcare systems, security, computing, and IoT applications. SynSense's neuromorphic processors overcome the limitations of traditional von Neumann computers by providing an unprecedented combination of ultra-low power consumption and low-latency performance.

Espansione Group is a medical technology company specializing in the development and distribution of innovative, non-invasive devices for ophthalmology. Their product portfolio includes proprietary photobiomodulation devices, light therapy systems using red, blue, and ultraviolet light, and diagnostic tools for eye screening. These solutions are designed to enhance patient outcomes by leveraging advanced, science-driven therapies, primarily serving the ophthalmology field.

Cardiawave, established in late 2014 through a collaboration between the Langevin Institute and the Georges Pompidou European Hospital, specializes in developing non-invasive ultrasonic medical devices aimed at treating heart valve diseases. The company's innovative technology focuses on real-time image guidance to address conditions such as calcified aortic stenosis, minimizing thermal injury and allowing for efficient treatment by clinicians. With a commitment to advancing medical care, Cardiawave has raised over €14 million since its inception to support product development and preclinical studies, paving the way for expected clinical trials to begin. The experienced management team, recognized for its excellence, continues to drive the company's mission to improve patient outcomes in cardiovascular health.

Cyclomics is a Dutch startup focused on revolutionizing cancer care through its proprietary circulating tumor DNA (ctDNA) detection technology. This innovative approach aims to provide faster and more reliable diagnoses, particularly for monitoring cancer recurrence and treatment responses, addressing critical clinical needs that current imaging methods struggle to meet. Cyclomics has developed a diagnostic kit, CyclomicsSeq, which offers superior performance compared to traditional radiological and physical examinations. The initial application of this technology targets head and neck cancers, where effective monitoring of treatment response and recurrence is vital for improving patient survival rates. By enabling accurate measurements and timely interventions, Cyclomics seeks to significantly enhance cancer diagnostics and patient outcomes.

Yakna develops neurorehabilitation applications and hardware professional education popularization of science.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

Nateo Healthcare, founded in 2016 and based in Toulouse, France, specializes in designing, developing, and manufacturing medical devices for the fields of gynecology and obstetrics. The company focuses on creating innovative connected medical devices and software that enable healthcare professionals to monitor the health of expectant mothers and their unborn babies. Among its key products is a belt equipped with ultrasound probes that can assess fetal positions, measure the mother's heart rate, and monitor uterine contractions. Additionally, Nateo Healthcare is working on a new generation of mobile and connected fetal heart rate monitors, which facilitate both hospital and home fetal telemonitoring, allowing for enhanced patient self-monitoring and tailored healthcare interventions.

Revamp Medical, founded in 2016, focuses on addressing the urgent unmet needs of patients suffering from acute heart failure, a condition that leads to over one million annual hospital admissions in the United States and incurs significant healthcare costs. The company has developed the Doraya™ catheter, a patented device designed to regulate vascular hemodynamics in these patients. This innovative solution targets issues such as diuretic resistance by managing preload and reducing central venous pressure, ultimately enhancing the efficacy of diuretics and facilitating progressive decongestion. Revamp Medical is backed by a team of experienced professionals with a strong background in medical technology startups, positioning the company to deliver an easily adoptable treatment option that addresses a critical gap in heart failure care.

Stemcis is a medical device manufacturer based in Saint-Denis, France, focused on the research and development of adipose tissue. The company specializes in creating surgical kits designed for the collection, treatment, and re-injection of fat cell preparations. Their work in tissue engineering encompasses both human and veterinary medicine, addressing various pathologies through innovative protocols and medical solutions. Through its commitment to advancing adipose tissue applications, Stemcis aims to enhance treatment options in the medical field.

Nasal is a technology-focused company that specializes in developing automated medical devices for the healthcare sector. It aims to enhance professional practices by providing tools that offer detailed insights into the structure and behavior of the nasal cavity. Through its innovative solutions, Nasal seeks to advance medical simulation technology, thereby assisting and training healthcare professionals. The company's efforts are geared towards improving the quality of care for patients and supporting the ongoing development of medical expertise.

PlatoScience ApS, founded in 2015 and located in Copenhagen, Denmark, specializes in neurostimulation technology through its product, the PlatoWork headset. This device employs transcranial direct current stimulation (tDCS), a non-invasive method that modulates neuronal activity by applying low-intensity currents to the scalp via electrodes. The technology aims to enhance synaptic plasticity and facilitate a targeted mindset, enabling users to achieve deep focus for various tasks. By making neurostimulation accessible and user-friendly, PlatoScience seeks to support mental health and improve cognitive performance, catering to individuals seeking to optimize their mental capabilities.

EarWays Medical Ltd. is an innovative company focused on developing ear-care solutions aimed at improving the well-being of children and adults globally. The company specializes in a medical device designed for the effective removal of earwax, utilizing a patented technology that features a flexible, coated helical tip for easy navigation in the ear canal. This device is suitable for both clinicians and home users, facilitating the management and extraction of cerumen. Backed by a team of experts in bioengineering, medical devices, and ear health, EarWays Medical is well-positioned to address the medical demand for accessible and effective ear care, helping to prevent temporary hearing loss caused by earwax buildup.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, enabling early intervention to prolong gestation and enhance neonatal health outcomes. Pregnolia serves pregnant women and gynecologists, aiming to ensure every woman experiences a happy, healthy, and informed pregnancy. The company's dedicated team, including Sabrina, Francisco, and Annette, is committed to completing clinical trials, navigating regulatory paths, and commercializing the device to support gynecologists in improving preterm birth risk assessment and management.

Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.

ODI Medical specializes in developing innovative technology for the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's medical device streamlines the collection of microvascular data and has diverse clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, and early detection of evolving sepsis. Additionally, the technology is useful for monitoring chronic wounds and conducting mass screenings for conditions such as Ebola, bird flu, and epidemic meningitis. By employing non-invasive techniques, ODI Medical enables healthcare professionals to enhance patient therapy through improved assessment of microcirculation.

Probiomedica is a company focused on developing innovative biomedical devices that integrate engineering, biology, photonics, and robotics for health and personal care applications. The company specializes in creating small swallowable capsules designed to emit light at specific wavelengths, utilizing the principles of Photodynamic therapy. This technology aims to enhance the photo-killing of harmful bacteria such as Helicobacter pylori, which is associated with conditions like gastritis, peptic ulcers, and gastric cancer. By employing these advanced photonic techniques, Probiomedica seeks to offer effective treatments that minimize reliance on pharmaceuticals and reduce the risk of drug-related side effects, thereby improving patient outcomes in the realm of gastrointestinal health.

Raytelligence AB, a subsidiary of Swedish Adrenaline founded in 2015, specializes in developing microwave sensors for the healthcare and industrial markets. The company focuses on vital sign monitoring, offering products such as the RayVS1 sensor, which is capable of monitoring heartbeat, movement, and body position. Raytelligence's innovative solutions include cloud-based signal processing and analysis services, facilitating home monitoring for users. The company has received recognition for its advancements, including a grant from the Swedish Innovation Bureau to support the development of its radar sensor technology. Since its inception, Raytelligence has successfully certified its sensor for home use and established partnerships for sensor development in various applications, including the road construction industry and e-Health initiatives. The team at Raytelligence combines expertise in industrial design and radar signal processing, positioning the company as a key player in the sensor technology sector.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

CardiacSense Ltd. is an Israeli company founded in 2012, specializing in the development of medical wearable devices aimed at monitoring heart arrhythmias and other critical health metrics. The company offers FDA and CE certified medical watches and wristbands that provide continuous, long-term, non-invasive monitoring of vital signs, including heart rate, respiratory rate, core temperature, oxygen saturation, and blood pressure. Utilizing advanced photoplethysmography (PPG) technology, CardiacSense's devices enable real-time diagnostics for various medical conditions, including atrial fibrillation, hypertension, chronic obstructive pulmonary disease (COPD), heart failure, sleep apnea, and infections such as COVID-19. By focusing on affordability and comfort, CardiacSense aims to enhance patient care and preventative measures within the healthcare industry.

Novagan Sàrl, founded in 2009 and based in Lausanne, Switzerland, specializes in the development and fabrication of semiconductor epitaxial wafers, particularly focusing on III-nitride materials. The company produces advanced optoelectronic components designed for high-power electronics and ultraviolet-visible applications, including new light sources based on gallium nitride (GaN) semiconductors. Novagan's products are aimed at industries such as medical imaging, displays, and projection systems, helping to transform innovative designs into functional products. The company seeks to establish long-term relationships with clients by providing timely, reliable, and cost-effective services that align with market needs.

Gondola Medical Technologies SA, founded in 2011 and headquartered in Stabio, Switzerland, specializes in the development of medical devices aimed at enhancing motor rehabilitation for individuals with Parkinson's disease. The company has created the GONDOLA™ device, which utilizes Automated Mechanical Peripheral Stimulation (AMPS) to address motor symptoms such as freezing of gait, slowness of movement, and balance issues. Designed for both home and clinical use, the device consists of two units worn on the patient's feet for short treatment sessions, typically lasting just a few minutes. The therapeutic benefits of the GONDOLA™ device can last between three to five days, and regular use—recommended twice a week—helps sustain these improvements over time. Gondola Medical Technologies is focused on advancing non-invasive treatment options in the fields of physiotherapy and neurological rehabilitation.

Bioengineering Laboratories SRL, based in Cantu, Italy, specializes in the design, development, manufacturing, and distribution of medical devices within the bioengineering sector. The company provides a diverse range of products, including those for urodynamics, dialysis, gynecology, extracorporeal circulation, and cardiac surgery. With over twenty years of experience, Bioengineering Laboratories focuses on innovative solutions and is committed to modern design principles in the medical field. The organization emphasizes a comprehensive understanding of market needs, an openness to new clinical techniques, and adherence to regulatory standards. Additionally, it offers advisory services related to the design, industrialization, and production of medical devices, ensuring a thorough approach to the engineering of life-enhancing technologies.

Bambi Medical is a MedTech company founded in November 2015 by Sidarto and Fabio Bambang Oetomo, aiming to alleviate pain and stress in pre-term infants while enhancing parent-child bonding. The company specializes in the design, development, and manufacturing of innovative products for Neonatal Intensive Care Units (NICUs) in hospitals. One of its key offerings is a wireless health monitoring device that tracks critical health metrics such as breathing, heart rate, temperature, and electrocardiogram (ECG) without the discomfort associated with traditional adhesive electrodes. This device facilitates maximum skin-to-skin contact between infants and their parents, allowing for effective monitoring of the baby's health while minimizing pain and skin irritation.

CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany, Vietnam and LAO PDR.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

DermoSafe is a Swiss company based in Cheseaux, founded in November 2012 by Philippe Held. The company specializes in innovative medical devices designed for the early detection and management of melanoma. Its primary product captures high-definition dermoscopic images of moles and pigmented lesions, allowing general practitioners to enter patient data and refer images to dermatology specialists via a secure web application. This platform facilitates the analysis of images, enabling specialists to provide electronic reports that assist in the early identification of melanoma and the management of treatment. DermoSafe's approach enhances collaboration between primary care practitioners, patients, and specialists, ultimately aiming to improve outcomes in melanoma care.

DELMIC specializes in correlative light and electron microscopy technology, focusing on applications in life and materials science research. The company offers a range of services, including cathodoluminescence, automated cryo-electron tomography workflows, and efficient electron microscopy solutions. These services are designed to enhance research capabilities by providing reliable and high-throughput methodologies, enabling researchers and organizations to gain insights more quickly and effectively. Through its innovative tools and integrated microscopy approaches, DELMIC aims to facilitate advancements in scientific research.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in developing microneedles for diagnostic and therapeutic applications. The company's primary product, Lymphit, is a wearable device designed to monitor lymphatic function, allowing for safe and scalable home-based use. Lymphit aims to facilitate the early diagnosis of secondary lymphedema, a potential complication of various cancer treatments. By enabling remote monitoring of lymphatic activity, the device empowers healthcare providers to diagnose conditions prior to the onset of swelling and to evaluate the most effective conservative treatments. This innovative approach not only enhances patient quality of life but also offers significant benefits to the healthcare system by optimizing treatment strategies and potentially reducing costs.

Eucardia is a company focused on developing innovative medical solutions for advanced heart failure therapy. Its flagship product, the Heart Damper, is a minimally invasive implantable cardiac device designed to offer a straightforward and cost-effective treatment option for patients suffering from advanced heart failure. By improving both the duration and quality of life for these patients, the Heart Damper also aims to alleviate the financial burden on healthcare systems associated with heart failure management.

Gogoa Mobility Robots specializes in developing wearable robotic solutions aimed at enhancing human mobility and supporting rehabilitation efforts. The company focuses on creating affordable and effective products, including exoskeletons designed for both industrial applications and health-related challenges. Their award-winning "Assist-As-Needed" control technology allows for seamless adaptation to various human movements, translating intention into action. Gogoa's exoskeletons are utilized in physical rehabilitation for patients recovering from conditions such as acquired brain damage, stroke, and spinal cord injuries, as well as in manufacturing to improve worker mobility and reduce injury risks. The Hank exoskeleton, a key product, has received CE Mark certification, enabling its commercial sale across Europe.

SurGuide is a medical device company with the goal to improve the surgical care for cancer patients. They support surgeons in their aim to achieve complete tumor removal, which is the biggest challenge in cancer surgery. Incomplete tumor removal, negatively affects patient outcome and necessitates additional treatment1. SurGuide’s technology addresses the problem that the information about the result of the operation becomes available only after several days. SurGuide’s technology will enable inspection of the resected tissue to determine if a tumor has been completely removed. The result of this inspection is reported to the surgeon, while the patient is still in the operating room. The report shows at which locations the tumor has not been completely removed. Based on this critical feedback the surgeon can decide to perform an additional resection at the indicated locations. In this way SurGuide’s technology will help to increase the rate of complete tumor resections.

Chromition Limited, based in Manchester, United Kingdom, specializes in developing and supplying advanced nanoparticle solutions for various commercial applications. The company offers a range of products, including Luminspheres, which are multi-colored photoluminescent polymer nanoparticles used in bio-imaging, anti-counterfeiting, and lighting; Elecspheres, semiconductor polymer nanoparticle inks utilized in displays, electronics, lighting, solar cells, and sensors; and Dielecspheres, high-k dielectric films that allow electronic devices to function at ultra-low voltages and reduced power consumption. Founded in 2014, Chromition's technology originated at the University of Manchester and was spun out to facilitate the commercialization of innovative optoelectronic products.

CorAssist Cardiovascular Ltd. is a clinical stage medical device company based in Haifa, Israel, focused on developing innovative products for treating heart failure with preserved ejection fraction and diastolic dysfunction. The company offers CORolla, an elastic self-expanding device designed to be implanted inside the left ventricle through minimally invasive procedures, including transapical and percutaneous approaches. This device enhances cardiac diastolic function by improving diastolic dynamics and filling performance without the need for an external power source. Additionally, CorAssist's ImCardia is a device that attaches to the external surface of the left ventricle and is implanted through a straightforward off-pump procedure, further contributing to the improvement of diastolic function in heart patients. Founded in 2003, CorAssist aims to address the unmet needs in heart failure treatment through its proprietary technology.

Preventicus GmbH, founded in 2014 and headquartered in Jena, Germany, develops innovative health solutions that utilize smartphone and smartwatch technologies to monitor vital parameters. The company's main product, Preventicus Heartbeats, is a class I medical device designed to identify atrial fibrillation, a condition that increases the risk of stroke. This smart screening solution allows users to check their heart rhythm quickly and conveniently, requiring no additional accessories. The software applications are certified medical devices and have demonstrated a level of accuracy previously achievable only by physicians, making them valuable for private users, corporate clients in occupational health management, and OEM customers. Preventicus focuses on early preclinical risk screening for lifestyle-related illnesses, including heart attacks and strokes, effectively enhancing personal health management.

Syrinjector LTD. is developing a full digital solution based on a novel portable automated syringe gun and software for rapid, controlled, and traceable mass injection of livestock. With digital capabilities and data management, this fully automated, highly accurate, and safety-conscious solution is a must for the next generation of livestock farmers. Their solution will gradually replace the current process of using steel syringe guns and off-line paper certifications.

RoboFit ApS is a Danish company located in Christiansfeld that specializes in the manufacture and marketing of a rehabilitation robot designed to assist individuals with very weak muscles in exercising their shoulder region. This innovative technology enables patients to train effectively by utilizing the full range of motion of the shoulder, making the rehabilitation process both measurable and motivational.

Filterlex Medical Ltd., established in 2015 and based in Yokneam, Israel, specializes in developing embolic protection devices for reducing stroke and other complications during catheter-based structural heart procedures. Its flagship product, CAPTIS, is a full-body embolic protection device designed for intuitive deployment and retrieval. The company aims to address the limitations of existing products through its next-generation technology, which deflects, captures, and removes embolic particles, thereby minimizing procedural risks. Filterlex is currently seeking seed funding to support its innovative medical device startup in the cardiovascular field.

AcouSort is a Swedish company specializing in the development and sale of laboratory products and integrated solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological samples. Its offerings cater to researchers and life science companies, focusing on the automated preparation of samples such as blood cells, bacteria, and extracellular vesicles. The technology is rooted in acoustofluidics research from the esteemed group led by Professor Thomas Laurell at Lund University's Department of Biomedical Engineering. Key products include AcouTrap, AcouWash, and AcouPlasma, which facilitate efficient handling of microscopic particles in microfluidic channels for research and diagnostic applications.

SamanTree Medical SA is a Swiss company specializing in the development of innovative medical microscopy devices aimed at enhancing cancer treatment and surgical outcomes. Founded in 2014 and based in Ecublens, the company focuses on micro-optics-based digital microscopy systems that provide an extensive field of view for various applications, including research, diagnostics, and surgery. Its flagship product, a surgical digital microscope, enables real-time visualization of cellular structures within living tissue, facilitating precise assessment of tumor margins. This technology allows surgeons to achieve full margin control and make informed decisions during procedures, ultimately improving resection accuracy, reducing re-operation rates, and decreasing overall procedure costs. By enabling immediate visualization of cancerous cells during surgery, SamanTree Medical's devices significantly enhance patient care and outcomes in cancer surgery.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

Trisol Medical specializes in developing innovative medical devices for the treatment of tricuspid regurgitation. The company focuses on its transcatheter tricuspid replacement valve, which features a nitinol frame and specially designed leaflets aimed at effectively addressing tricuspid regurgitation while preserving the function of the right ventricle. Through its advanced technology, Trisol Medical offers comprehensive solutions for managing tricuspid regurgitation and right ventricle dysfunction, enhancing patient outcomes in the field of cardiac care.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Noonee is a pioneering company based in Switzerland, recognized as the first supplier of Wearable Ergonomic Mechatronic Devices (WEMDs). Founded in 2014, the company focuses on enhancing ergonomics in the manufacturing sector through innovative devices akin to exoskeletons. Its flagship product, the Chairless Chair, allows users to adopt active sitting, standing, and walking positions without the need for traditional seating, addressing the needs of workers, particularly those suffering from back pain. The development of this device involved ongoing collaboration with corporate clients and end users to ensure practical functionality. In 2016, noonee expanded its operations by establishing noonee germany GmbH, marking the beginning of its global rollout.

PVOH Polymers Ltd is a materials supply and development business at the leading edge of water soluble biodegradable polymer technology. They provide custom-designed formulations to suit their client’s individual requirements. Since being founded in 2009, they are currently working in a wide range of industries covering, detergent and home care controlled release, crop protection, single use medical devices, defence technology, personal health care, gelatine replacement drug delivery,angling and commercial bait delivery soluble devices.

Abanza Tecnomed SL is a Spanish company based in Mutilva Alta that specializes in the research and development of medical instruments and devices, particularly in the field of sports medicine. Founded in 2014, the company focuses on creating advanced surgical instruments for knee ligament reconstruction. Abanza Tecnomed emphasizes biomedical innovation and is supported by a multidisciplinary R&D team and a top-tier medical advisory board, ensuring the precision and safety of its products. The company is dedicated to producing cutting-edge devices that enhance the efficiency and effectiveness of medical professionals in their practices.

GyroGear is a multidisciplinary team composed of designers, engineers, and medical professionals focused on developing innovative solutions for individuals with hand tremors caused by Parkinson's disease and essential tremor. Their flagship product, the GyroGlove, is a wearable device that utilizes advanced aerospace-grade gyroscopes to mechanically stabilize hand tremors. By addressing this critical issue, GyroGear aims to enhance the quality of life, independence, and dignity of those affected by these conditions. The company is dedicated to providing an effective and straightforward solution for managing hand tremors, thereby improving daily functioning for its users.

Nimble Robotics designs and sells innovative medical devices for rehabilitation.

Neurosteer has developed a medical-grade wearable device and cloud-based system aimed at the early detection and treatment of neurological disorders. The solution features an adhesive forehead strip linked to a pocket-sized sensor that wirelessly transmits brain activity data to the cloud for processing. Utilizing advanced algorithms, the system decomposes a single EEG channel into over 100 individual components for real-time analysis, which is displayed on a web-based dashboard. Neurosteer's primary focus is on identifying early signs of conditions such as Parkinson's, Alzheimer's, dementia, and epilepsy. This innovative approach allows for more affordable screening, continuous monitoring of patients, and enhanced neurostimulation and drug selection, ultimately improving the treatment outcomes for neurological disorders and optimizing clinical trials.

S.T.Stent is a medical device company based in M.P. Misgav, Israel, founded in 2013. The company specializes in developing a composite removable sinus stent intended for placement in the ethmoid sinus after functional endoscopic sinus surgery (FESS), a procedure commonly performed to treat chronic sinusitis. The stent is designed to keep the surgical cavity open during the healing process, addressing challenges such as post-surgery scarring and stenosis, which can hinder recovery. A key feature of S.T.Stent's innovation is the removable nature of the device, allowing patients or physicians to decide when it should be taken out. This removal can be performed in an office setting without anesthesia, making it a minimally invasive option for patients.

Paragate Medical is an Israeli company based in Nazareth Illit that focuses on designing and developing innovative implantable devices aimed at providing continuous relief for patients suffering from congestive heart failure and fluid overload related to heart and kidney failure. The company's minimally invasive system is laparoscopically implanted and functions as a mechanical bypass to the kidneys, allowing for the effective removal of excess fluid from the body. This device offers healthcare providers a continuous and non-aggressive option for managing fluid levels, enabling patients to maintain balance in their fluid levels from the comfort of their homes.

NeoMedLight focuses on developing innovative medical devices that leverage phototherapy technology, specifically through the use of woven optic fibers known as the Fabric of Light (Lightex®). Originally developed by Brochier Technologies, NeoMedLight holds exclusive rights to this technology in the healthcare sector. The company initially created a fiber-optic device aimed at treating neonatal jaundice but is expanding its applications to include conditions such as mucositis, dermatitis, wound healing, and pain management. By providing a precise and consistent method of treatment, NeoMedLight aims to enhance therapeutic efficiency while minimizing side effects, ultimately improving patient outcomes across various medical fields.

liberDi is an Israeli company that specializes in portable automatic peritoneal dialysis systems designed for patients with end-stage renal disease. The company offers an innovative all-in-one Digital Dialysis Clinic that enables patients to manage their own dialysis with the help of an Intelligent Dialysis Assistant and remote medical supervision. This system allows patients to perform peritoneal dialysis from various locations, including their homes, offices, or while traveling, thereby enhancing their quality of life and reducing reliance on traditional in-clinic care. Founded in 2014 by a team of experts in science and medicine, liberDi aims to free dialysis patients from the constraints of frequent visits to expensive clinics. Its technology not only empowers patients but also helps clinics optimize their operations and reduce costs, creating a comprehensive platform for renal care that benefits both patients and healthcare providers.

EIO Biomedical is a biotechnology company based in Nazareth, Israel, focused on developing a medical device aimed at preventing post-surgical adhesions. Established in 2016, the company has created a spray containing essential blood clotting proteins that promotes targeted clotting at the wound site. This innovative product alters the formation of the fibrin network by cross-linking fibrin to establish a barrier against cell adhesion. As a result, it enables surgeons to conduct both laparoscopic and open surgeries with reduced concern for significant surgical complications. EIO Biomedical has received financial backing from NGT3 VC and the Israeli Office of Chief Scientist, highlighting its potential impact in the field of surgical procedures.